Biosynex SA (ENXTPA:ALBIO) bid to acquire remaining 74.93% stakes in Theradiag SA (ENXTPA:ALTER) on September 23, 2022. Biosynex SA will acquire the remaining shares at €2.30 per share. Fieldfisher is acting as legal counsel to Theradiag in this transaction.

Biosynex SA (ENXTPA:ALBIO) completed the acquisition of 40% stakes in Theradiag SA (ENXTPA:ALTER) on January 12, 2023. The offer will be reopened for a period of at least 10 trading days for remaining stake.